Ivan Krivega

Scientist, cyclist, runner, and movies/books consumer. Views are my own.

[Ivan Krivega @IvKrivega]

@SonotheraI41798 oral presentation focuses on the safe delivery of DNA expression vectors to the liver in NHP using its RIPPLE delivery technology. Study results demonstrated durable protein expression of up to 65% of normal circulating FVIII

#ASH25

https://t.co/3CPx9Yeve5

[Ivan Krivega @IvKrivega]

@GuyYoungMD: "Sounds like Since Fiction"

Looking forward to get the data discussed today at 5:15pm, session 801.

#ASH25 #HemophiliaA #GeneTherapy #nonviral

[Ivan Krivega @IvKrivega]

#ASH25

No effect or neutralizing antibodiez on efficacy of AAV gene therapy

#AAV #GeneTherapy

[Ivan Krivega @IvKrivega]

Seville

[Ivan Krivega @IvKrivega]

@yo_arfi Publicly disclosed -> in the public domain. Don't want to be shared, don't present 😉

[Ivan Krivega @IvKrivega]

Base Editors make double-stranded brakes and chromosome rearangements

#ESGCT2025 #BaseEditors #OffTagets

[Ivan Krivega @IvKrivega]

Circular RNA with embedded aptmers. Went strait to human testing after positive results on rodent models. Chinese biotech!

https://t.co/5FlWxRvydg

#circRNA #aptamers #ChineseBiotech

[Ivan Krivega @IvKrivega]

@zhaoweiasu Please share refences showing lack of DSB for ABE

[Ivan Krivega @IvKrivega]

Clinical limitations of AAV microdystrophin gene therapy

Jeffrey S. Chamberlain from
@uwsomwwami

#ESGCT2025 #DMD #GeneTgerapy

[Ivan Krivega @IvKrivega]

Efficient EGFP reporter transgene delivery to NHP T cells by LNP. Next step is delivering the CAR in vivo

#ESGCT2025 #InVivoCART

Cecilia Cotta-Ramusino @TesseraTx

[Ivan Krivega @IvKrivega]

Flamenco night @TeatroSevilla

[Ivan Krivega @IvKrivega]

Liver directed Klotho overexpression fails to protect from ALS in mice

Sergi Verdes, Universitat Autonoma de Barcelona

#ALS #GeneTherapy #Klotho

[Ivan Krivega @IvKrivega]

ZFP genome editors for suppressing prion gene expression. Surprisingly similar to @SangamoTx

@DevermanLab
#EpigenomeEdirors #prion ##ESGCT2025

[Ivan Krivega @IvKrivega]

StichR technology for expressing minidystrophin in mouse skeletal muscle. Douglas Anderson from @UR_Med

#ESGCT2025 #DMD ##GeneTherapy

[Ivan Krivega @IvKrivega]

Official press release for @SonotheraI41798 presentation @ #ESGCT2025.

Results show high levels of durable human dystrophin protein expression exceeding
50% of endogenous levels have been achieved in NHP.

Poster Session 2, Oct 9th. Poster P0266.

#Dmd #GeneTherapy #nonviral

[SonoThera @SonoThera_]

The ability to deliver targeted, full-length human dystrophin to skeletal, heart and diaphragm muscles in a durable, safe, redosable and noninvasive manner shows how UMD can overcome all of the challenges of current gene therapy delivery options. Learn more: https://t.co/69afv3v7Ps #ESGCT2025 #newdata #geneticmedicine #ultrasound #microbubble #nonviral #duchennemusculardystrophy

[Ivan Krivega @IvKrivega]

Heading to #ESGCT2025 to share the @SonotheraI41798 team’s latest advances in non-viral delivery of gene therapy vectors expressing full-length dystrophin gene.

#DMD #GeneTherapy #Nonviral

[Ivan Krivega @IvKrivega]

@DarioLeff @Sarepta For safety and efficacy reasons, I assume.

[Ivan Krivega @IvKrivega]

@DarioLeff @Sarepta Don't see that in the exclusion criteria
https://t.co/V9PIrfWsTb

Can you elaborate on which exact mutations are excluded?

[Ivan Krivega @IvKrivega]

@PoseidaThera collaboration with @TakedaPharma on #nonviral #GeneTherapy
https://t.co/v148L3Maq4

[Ivan Krivega @IvKrivega]

@DarioLeff @Sarepta https://t.co/WMBSTmHHzk